Abstract
Four reports in Diabetologia presented data on the association between hypoglycaemic agents and the risk of cancer. One study showed a higher risk of cancer overall in subjects with diabetes receiving insulin or sulfonylureas than in those on metformin. In another study, the risk of cancer overall increased with dose for any type of insulin and, among high doses, insulin glargine (A21Gly,B31Arg,B32Arg human insulin)-only users had a higher risk than subjects on human insulin. In two studies, users of insulin glargine alone had a higher risk of breast cancer than those on other insulins, a third study found no association. Whether these associations are causal or at least partially explained by chance or biases such as confounding, reverse causation, selection or detection biases is arguable. Current epidemiological evidence is insufficient to confirm a carcinogenic effect of specific insulins on specific cancers. However, the potential dose effect of insulin overall, and insulin glargine in particular, on colon and breast cancer deserves further attention.
Abbreviations
- OHA:
-
Oral hypoglycaemic agent
References
Zendehdel K, Nyrén O, Ostenson C, Adami H, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800
Adami H, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314
Yang Y, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050
Chung YW (2008) Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case–control study in Korea. Dis Colon Rectum 51:593–597
Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
Bowker S, Majumdar S, Veugelers P, Johnson J (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258
Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777
Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744
Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765, Erratum Diabetologia 52: 2469
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52:1745–1754
Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499–2506
Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin determir: a meta-analysis. Diabetologia 52:2507–2512
Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511–512
Adami HO, Chow WH, Nyrén O et al (1996) Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472–1477
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript. S. Hernández Díaz has received unrestricted research and training grants from multiple pharmaceutical companies, none in relation to oral hypoglycaemic agents.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hernández-Díaz, S., Adami, HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53, 802–808 (2010). https://doi.org/10.1007/s00125-010-1675-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-010-1675-2